Evaluation of the Pharmacokinetics and Safety of NT-814 in Post-Menopausal Women With Vasomotor Symptoms
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 03 Jul 2017
At a glance
- Drugs NT 814 (Primary)
- Indications Hot flashes; Vasomotor symptoms
- Focus Adverse reactions; Pharmacokinetics
- Acronyms RELENT1
- Sponsors NeRRe Therapeutics
- 27 Jun 2017 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017.
- 27 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Jul 2017.